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Dear Editor,
The accumulation of fatty acids in the hepatocytes,
which is caused by different pathophysiologic mecha-
nisms, is known as fatty liver disease. For instance,
metabolic syndrome or obesity, in which lipolysis is sup-
pressed as a result of hyperinsulinemia, would conse-
quently provoke non-alcoholic fatty liver disease (NAFLD)
or the more severe non-alcoholic steatohepatitis (NASH). In
the long-term, this condition could result in liver cirrho-
sis (1, 2). However, when it occurs during the gestational
period, it is termed acute fatty liver of pregnancy (AFLP).
Rather than an indolent chronic disease, AFLP is a devas-
tating condition that can rapidly progress to fulminant
hepatic failure with associated coagulopathy or hepatic en-
cephalopathy. In this scenario, the lives of two individuals
(i.e., mother and infant) are inevitably jeopardized (3, 4).
With regards to AFLP, the underlying pathogenesis is
unique. Maternal-fetal interactions are mostly blamed
for the impaired fatty acid beta-oxidation. Indeed, fatty
acid oxidation defects have been associated with mater-
nal liver dysfunction (5-8). These defects are autoso-
mal recessive. The most common such defect is an in-
herited deficiency of a mitochondrial enzyme, namely
long-chain 3-hydroxyacetyl coenzyme-A dehydrogenase
(LCHAD), which leads to the accumulation of toxic long-
chain fatty acids in the woman’s liver. Hepatocyte failure
will ultimately ensue. The oxidative stress begins in the
placenta (3, 8), although it can also affect the neonate (9).
Since its initial description in 1940, AFLP has been con-
sidered an obstetric emergency that can lead to multi-
ple organ failure in a short time unless it is diagnosed
promptly (3, 4). The diagnosis of AFLP is based on the
Swansea criteria, which represent a constellation of signs
and symptoms, along with abnormal lab tests such as el-
evated aminotransferases (10). As a disease of the last
trimester of pregnancy, AFLP presents with intriguing fea-
tures, including non-specific gastrointestinal symptoms
that are easily overlooked or misdiagnosed (3, 7, 11). There-
fore, defining appropriate screening guidelines for outpa-
tient pregnant women could be life-saving. The 34th week
of gestation has been recommended for this purpose (12).
As the first step, liver and coagulation function tests could
be performed for any pregnant woman who complains of
new-onset gastrointestinal symptoms such as abdominal
pain, nausea, and vomiting. If abnormal results are found,
further tests should be performed, including renal func-
tion tests, blood glucose level, and abdominal ultrasound
(5, 11-13).
Unlike HELLP syndrome and severe preeclampsia,
which are the other potentially fatal disorders unique to
the last trimester of pregnancy and puerperium, AFLP is
a true hepatic dysfunction. Hence, impaired coagulation
function tests should be more prominent as they could
have prognostic value (5, 13, 14). In a study by Meng et
al. involving 43 patients managed in a tertiary care cen-
ter, the levels of prothrombin time, plasma fibrinogen,
and platelet counts were correlated with the recovery time,
while the leukocyte count, serum blood glucose, and hep-
atic aminotransferase levels showed no value in predict-
ing the prognosis (14). Emergency termination of the preg-
nancy is the cornerstone of AFLP management, with ce-
sarean section being the preferred mode of delivery. Nev-
ertheless, the correction of concurrent coagulopathy with
adequate blood products should be considered first (4, 7,
8). The transfusion of fresh frozen plasma (FFP), cryopre-
cipitate, or platelet concentrates in the case of abnormal
conventional tests like prothrombin time (PT), activated
partial thromboplastin time (aPTT), or fibrinogen could
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly
cited.
Gorginzadeh M et al.
prevent further bleeding complications. However, there
remain some concerns regarding fluid overload, acute
lung injury, and infection as a result of the use of these
products (15). Moreover, the current standard coagulation
tests are considered to be only weak predictors of bleed-
ing in critically ill patients; therefore, additional methods
such as thromboelastometry could be employed (16, 17).
Thromboelastometry has been applied in the early predic-
tion of bleeding complications in severely ill patients. In a
case report by Crochemore et al., this method was found to
efficiently detect the hypocoagulable state and diminished
fibrinogen function quality at the beginning of surgery.
Fibrinogen and prothrombin complex concentrates were
administered to the patient and the cesarean section was
performed without any major bleeding (17). The injection
of recombinant factor 7 along with supportive care man-
agement in an intensive care unit has been also recom-
mended (18). Through the application of plasma exchange
and plasma perfusion during the early phase of AFLP, the
progression of the disease can be stopped or reversed (19).
Another important point concerns the deficiency of vi-
tamin K observed in neonates born to women with AFLP.
There has been a case report of severe intracranial bleed-
ing due to early vitamin K deficiency in a neonate whose
mother was diagnosed with AFLP. In a study by Arya et
al. (20), it was suggested that monitoring infants born to
these women could be helpful in reducing their morbidity
and mortality.
In sum, it is important to note that the management
of AFLP is a multidisciplinary progress that necessitates ac-
tive and prompt intervention by gastroenterologists and
anesthesiologists along with obstetricians and neonatolo-
gists in a tertiary care center equipped with an intensive
care unit (9, 13, 18). While as deleterious as both preeclamp-
sia and HELLP syndrome, AFLP differs in that its manage-
ment requires more than just the termination of the preg-
nancy. Hence, the monitoring of both the mother and her
neonate for several days following delivery is vital. Further-
more, considering the fact that unlike more benign dis-
eases such as NAFLD or NASH, the progression to cirrhosis
in AFLP has not been reported until now (1, 3), the timely
intervention of professionals should result in there being
no long-term sequelae.
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